Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Co-Delivery of Stat3 Sirna and Methotrexate in Breast Cancer Cells Publisher Pubmed



Shakeran Z1, 2 ; Varshosaz J3 ; Keyhanfar M1 ; Mohammadbeigi H2, 4 ; Rahimi K2, 5 ; Sutherland DS2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Biotechnology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran
  2. 2. iNANO Center, Aarhus University, Aarhus C, Denmark
  3. 3. Department of Pharmaceutics, School of Pharmacy and Novel Drug Delivery Systems Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Department of Biotechnology and Biomedicine, Technical University of Denmark, Kgs. Lyngby, Denmark
  5. 5. Department of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark

Source: Artificial Cells, Nanomedicine and Biotechnology Published:2022


Abstract

Co-delivery of anticancer drugs and biologics can provide synergetic effects and outperform single delivery therapies. Here, a nanoparticle (NP) system for co-delivery of methotrexate (MTX) and STAT3 siRNA has been developed and tested in vitro. Mesoporous silica nanoparticles (MSNs) were functionalized with chitosan (ch) by covalent grafting mediated by aminopropyl triethoxysilane (APTES) via glutaraldehyde as the linker. Co-delivery of MTX and STAT3 siRNA to MCF7 cells was demonstrated in cells by flow cytometric analysis and confocal laser scanning fluorescence microscopy for use in breast cancer treatment. MTX either competitively inhibits the dihydrofolate reductase (DHFR) receptor or suppresses the STAT3 metabolic pathway. STAT3 protein plays an essential role in cell division, proliferation and survival. Reduction of the protein by both MTX and STAT3 siRNA, achieved by chMSNs, significantly decreased the viability of breast cancer cells compared to single treatments alone. Cellular uptake of modified NPs was increased over time when additional free MTX was added implicating the DHFR receptor in uptake. In addition, protein corona compositions coated the NPs outer surface, were different between the NPs with and without drug potentially modulating cellular uptake. This study is the first report on co-delivery of MTX and STAT3 siRNA by chitosan modified MSNs. © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
Experts (# of related papers)
Other Related Docs
14. A Concise Review on Cancer Treatment Methods and Delivery Systems, Journal of Drug Delivery Science and Technology (2019)
15. Plga-Peg-Ra-Based Polymeric Micelles for Tumor Targeted Delivery of Irinotecan, Pharmaceutical Development and Technology (2018)
16. Recent Progress in Cancer Immunotherapy: Application of Nano-Therapeutic Systems, Journal of Drug Delivery Science and Technology (2024)
25. Lipoprotein Like Nanoparticles Used in Drug and Gene Delivery, Current Pharmaceutical Design (2016)